Companies that stumble with their manufacturing can count on a competitor picking up some market share while they are down. Fresenius is trumpeting the fact that it has done just that.
Shortages of life-sustaining cancer drugs have become an industry concern but to essentially announce a shortage even as a potential blockbuster drug is being approved for release takes the industry into new territory.
Manufacturing problems and disruptions at Novartis ($NVS) plants in Nebraska and Canada led to shortages that have left an ugly trail of unhappy healthcare providers and consumers.
A non-FDA approved drug from India and U.S. contract manufacturers will address cancer drug shortages resulting from production and quality problems at Ben Venue Laboratories ' now notorious Ohio...